Experts name 2 ASX growth shares for investors to buy now

Here are two growth shares that could be in the buy zone according to experts…

| More on:
a business person in a suit and tie directs a pointed finger upwards with a graphic of a rising bar graph and an arrow heading upwards in line with the person's finger.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're searching for growth shares to buy, then it could be worth considering the two listed below.

Here's why experts are saying that these ASX growth shares are in the buy zone now:

Readytech Holdings Ltd (ASX: RDY)

The first ASX growth share to look at is Readytech. It owns a portfolio of enterprise software businesses across several market verticals such as higher education and local government.

The team at Goldman Sachs note that these businesses operate in market niches that are under-served by both large and small enterprise software competitors. This has been supportive of growing recurring revenues and very low levels of churn.

Its analysts commented:

In our view, RDY will continue to grow mid-teens organically while making accretive acquisitions (such as IT Vision), with profitability underpinned by solid software metrics including low churn at ~3% and high LTV/CAC.

RDY serves defensive end markets (e.g. higher education, local government) and has high recurring revenue (>85%) which should protect the company's earnings profile in an economic downturn.

Goldman Sachs has a buy rating and $4.60 price target on ReadyTech's shares.

ResMed Inc (ASX: RMD)

Another ASX growth share that has been rated as a buy is ResMed. It is a sleep treatment focused medical device company with an industry-leading portfolio of products.

Citi is a fan of the company and notes that the company has announced plans to expand its growing software business into Europe via the acquisition of Medifox Dan for US$1 billion. It also highlights that ResMed's shares are trading on lower than average multiples, potentially creating a buying opportunity for investors.

Our FY23-24E EPS increases by <1% and Target Price reduces to $34.50 (from $35.50) as a result of incorporating Medifox Dan acquisition into our forecasts. RMD is currently trading at PE of ~28x FY24E, below historical avg of ~32x.

Maintain Buy. This is RMD's third major acquisition in the SaaS segment after Brightree (Apr'16) and MatrixCare (Nov'18). ResMed paid US$800m or ~19x EBITDA for Brightree and ~US$750m or 25x EBITDA for MatrixCare. The Medifox Dan acquisition should allow RMD to expand its SaaS business footprint outside the U.S.

Citi has a buy rating and $34.50 price target on ResMed's shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Readytech Holdings Ltd and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Readytech Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

happy investor, share price rise, increase, up
Growth Shares

2 top ASX growth shares for explosive potential in 2025

These stocks look exciting and compelling to me.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Share Market News

Brokers say these ASX 200 growth stocks could rise 50% to 70%

Analysts think these shares could be dirt cheap and destined to generate big returns.

Read more »

happy investor, share price rise, increase, up
Growth Shares

3 fantastic ASX 200 growth shares to buy in 2025

Analysts have good things to say about these buy-rated shares.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Growth Shares

The ASX 200 stock with 'a $200 billion gross profit opportunity'

Experts believe this stock has excellent potential.

Read more »

A young girl and boy drinking milk in a garden setting
Growth Shares

2 ASX growth shares set to skyrocket in the next 12 months

These stocks have a lot of potential according to experts.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 no-brainer ASX 200 shares to consider buying with just $1,000

Analysts rate these top stocks very highly. Let's find out why.

Read more »

A happy laughing surfer couple surfing together.
Growth Shares

If I were in my 20s, I'd buy these ASX shares for growth

I think these investments could be great picks for younger Aussies.

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Growth Shares

Invest $5,000 into these ASX 200 shares in 2025

Analysts think these shares could be top options for an investment in 2025.

Read more »